Advertisement

Topics

Numis Securities Limited Company Profile

18:55 EDT 22nd June 2018 | BioPortfolio

Numis Securities Limited ("Numis") is a rapidly growing investment banking and institutional stockbroking business providing a premium service to corporate and institutional clients. It is the trading subsidiary of Numis Corporation Plc, whose shares are quoted on the Alternative Investment Market of the London Stock Exchange Our aim is to provide a premium service to our corporate and institutional clients. We do not provide services to individual private customers.
Our services are research driven and concentrate on UK market sectors in which we have proven expertise. They comprise a full range of Corporate Finance, Institutional Stockbroking, Market Making and Research services. As well as our head office in Cheapside in the City of London we are represented in Liverpool, where our analysts and specialist sales team covering the Consumer sector are located and where part of our Speciality Financials expertise can be found

Location

Cheapside House138 Cheapside
London
London
EC2V 6LH
United Kingdom

Contact

Phone: 020 7776 1500


News Articles [201 Associated News Articles listed on BioPortfolio]

Numis Securities tempers recommendation on Ocado following “solid” trading update

Numis analysts said: “Although we lower our recommendation from Buy to Add today to reflect the strong move in the share price (+130% over the last 4m), we remain positive"

Ocado to secure more partnerships after bagging deal with Sweden's ICA, says Numis

Numis upgraded its rating on Ocado to ‘buy’ from ‘add’, saying it believes Ocado is building a “very valuable business”.

EMIS has fallen too far, says house broker Numis Securities

CEO Andy Thorburn is focused for now on improving underlying operating procedures and performance, including a focus on the replacement GP systems contract for England, now perhaps 15-18 months away

Numis Securities trims rating for Hikma Pharmaceuticals to ‘add’ from ‘buy’ on valuation grounds after update

The City broker, however, raised its target price for the FTSE 250-listed firm to 1,560p, up from 1,300p previously after updating its sum-of-the parts valuation for the group

Numis Securities trimmed rating for Hikma Pharmaceuticals to ‘add’ from ‘buy’ on valuation grounds after update

The City broker, however, raised its target price for the FTSE 250-listed firm to 1,560p, up from 1,300p previously after updating its sum-of-the parts valuation for the group

Western Gas Partners, LP Announces Pricing Of $1.1 Billion Of Senior Notes

Mizuho Securities USAInc., Credit Suisse Securities ( USA) LLC, MUFG Securities Americas Inc., and TD Securities ( USA) LLC are acting as Read more...

hVIVO upgraded to ‘Buy’ by Numis despite CEO resignation

In a note to clients, analysts for the broker said the biotech firm had indicated a more coherent strategy that reflected value despite recent weak share performance

hVIVO upgraded to Buy by Numis despite CEO resignation

In a note to clients, analysts for the broker said the biotech firm had indicated a more coherent strategy that reflected value despite recent weak share performance

PubMed Articles [2 Associated PubMed Articles listed on BioPortfolio]

Sunlight and Other Disinfectants: Disclosure Obligations under the Federal Securities and Drug Regulatory Regimes.

Drug development requires patience. Beyond the inherent uncertainty of the development process itself, U.S. drug developers must comply with the regulatory approval process overseen by the U.S. Food a...

Land-Water-Food Nexus and indications of crop adjustment for water shortage solution.

While agriculture places the greatest demand on water resources, increasing agricultural production is worsening a global water shortage. Reducing the cultivation of water-consuming crops may be the m...

Clinical Trials [1 Associated Clinical Trials listed on BioPortfolio]

Conjugate Vaccine Against Meningococcus C a Brazilian Project

TYPE / DESIGN STUDY: Clinical trial phase II / III, randomized, double-blind, national multi-center, with a total of 1,644 research participants stratified into 3 groups according to age f...

Companies [225 Associated Companies listed on BioPortfolio]

Numis Securities Limited

Numis Securities Limited ("Numis") is a rapidly growing investment banking and institutional stockbroking business providing a premium service to corporate and institutional clients. It is the trading...

Hilltop Securities Inc.

Hilltop Securities Inc., a member of NYSE, FINRA and SIPC, delivers the forthright advice and tailored solutions necessary for municipal issuers, institutions, broker-dealers and ...

Seaview Securities LLC

Seaview Securities LLC is a specialty investment bank assisting life sciences companies with private placements, public offerings, M&A and strategic advice.

Microsulis Medical Limited

Founded in 1997, Microsulis Medical Limited is a UK-based medical device company that exploits specialist intellectual property in medical microwave design to create therapeutic d...

LaSalle St. Securities, LLC ·

Like most top firms in this industry, LaSalle St. Securities offers a broad array of investment products, services and technology. But at the heart of LaSalle St. Securities is a group of seasoned pr...

More Information about "Numis Securities Limited" on BioPortfolio

We have published hundreds of Numis Securities Limited news stories on BioPortfolio along with dozens of Numis Securities Limited Clinical Trials and PubMed Articles about Numis Securities Limited for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Numis Securities Limited Companies in our database. You can also find out about relevant Numis Securities Limited Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Corporate Database Quicklinks



Searches Linking to this Company Record